Yet, in one this was highly significant ( Engels et al , 2004 ) whereas in the other, although docetaxel clearance decreased 2–4-fold in 25% of the patients, thus increasing the risk for severe neutropenia, it was not ( Van Veldhuizen et al , 2003 ).
← all excerpts
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
1
—
—